Filing Flows › Health Care › QuidelOrtho (QDEL)
QuidelOrtho (QDEL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · QuidelOrtho (QDEL) Q3 2026 earnings results →
Q3 2026 Revenue down 12% year over year to $619M · 9¢ of every $1 of revenue lost · operating margin -1.2%
QuidelOrtho made $619M in Q3 2026 (-12% Y/Y). Operating margin -1.2%, net loss $53.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $618.9M in Q3 2026, down 12% year over year and down 2% from the previous quarter.
Operating costs exceeded revenue by $7.5M, an operating margin of -1.2%. Total costs fell 55% while revenue fell 12%. The quarter ended with a net loss of $53.8M, narrower than the previous quarter's $92.9M loss. Net interest and other expense of $55.4M was the main reason.
Operating cash flow was $19.6M. Non-cash charges added back $119.6M of depreciation and amortization and $12.0M of share-based compensation. Working capital and other items used $58.2M. After acquisitions of property, plant, equipment, investments and intangibles (capital expenditures), net ($19.3M), free cash flow as the company reports it was $300K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $619M | -12% | -1.2% | −$53.8M | $19.6M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $631M | +3% | -3.5% | −$92.9M | −$111M |
| Q1 2026 | 10-Q | May 6, 2026 | $620M | -10% | -5.1% | −$91.8M | −$33.0M |
| Q4 2025 | 10-K | Feb 19, 2026 | $724M | +2% | -9.2% | −$131M | $132M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $700M | -4% | -100.7% | −$733M | −$45.5M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $614M | -4% | -29.4% | −$255M | −$46.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $693M | -3% | 4.7% | −$12.7M | $65.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About QuidelOrtho
All references to “the Company,” “we,” “our” and “us” in this Annual Report refer to QuidelOrtho Corporation (“QuidelOrtho”) and its subsidiaries. References to “fiscal year ended 2025,” “fiscal year ended 2024” and “fiscal year ended 2023” in this Annual Report refer to the Company’s fiscal years ended December 28, 2025, December 29, 2024 and December 31, 2023, respectively. Refer to the Summary of Abbreviated Terms at the end of this Annual Report for definitions of terms used throughout this Annual Report. Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes.
In its own words, from its 10-K, filed Feb 19, 2026.
QuidelOrtho against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -12% against the peers' median +2%. Operating margin: -1.2% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: QuidelOrtho 10-Q on SEC EDGAR · CIK 1906324 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns QDEL and who is buying
More on QDEL
- How QuidelOrtho makes money: revenue by segment
- QuidelOrtho next earnings date and what analysts expect
- QuidelOrtho stock forecast, price target and fair value
- Who owns QuidelOrtho stock: holders, funds and Congress trades
- QuidelOrtho guidance and outlook
- Is QuidelOrtho a takeover target? LBO and rumors
- QuidelOrtho recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results